We are here to extend our lives by THINKING DIFFERENT

Tuesday, August 31, 2010

Pharmaxis in deal to support launch of cystic fibrosis drug

Pharmaxis in deal to support launch of cystic fibrosis drug

Eli Greenblat

August 31, 2010 - 4:07PM

Biotech company Pharmaxis says it has finalised a strategic marketing and sales service agreement for the commercialisation of its cystic fibrosis drug, Bronchitol, for use in Europe.

The company said this morning that ahead of anticipated regulatory approval for Bronchitol, it had signed a six-year agreement with the highly respected Quintiles organisation to support the launch and commercialisation of the product in Western Europe.

Pharmaxis acting chief executive Gary Phillips said: “This important development means that Pharmaxis will move into the key European markets with a clear commercialisation plan. We will be bringing on board the European expertise and capabilities of a well recognised team of leaders in the field.

“Bronchitol is a new advance in the treatment of cystic fibrosis and it’s vital that we engage fully with the CF communities, healthcare professionals, funding bodies and governments across Europe as efficiently as possible.’’

Quintiles is a global biopharmaceutical services company offering clinical, commercial, consulting and capital solutions. The Quintiles network employs 20,000 people across 60 countries.

Two completed Phase 3 clinical trials of Bronchitol have demonstrated early and sustained improvement in lung function in people with cystic fibrosis. The product has been granted orphan drug designation by the European Medicines Agency, which helps accelerates its development and path to commercialisation.

Pharmaxis plans to launch Bronchitol across Western Europe, initially in Germany and the UK in the first quarter of 2011.

The Pharmaxis contract sales representatives will be supported and managed by the Quintiles organisation throughout Western Europe while marketing and market support will be managed by the Pharmaxis office in the UK.



No comments:

Post a Comment